Part 2 Authorisation of autogenous vaccines, blood-banks, stem cell centres and products manufactured under the cascadeF1
United Kingdom
- 14Authorisation to manufacture specific veterinary medicinal products
- 15Prohibition
- 16Personnel
- 17Process of authorisation
- 18Authorisation in relation to blood banks
- 19Authorisation in relation to stem cells
- 20Authorisation in relation to products for administration under the cascade
- 21Suspension, compulsory variation or revocation of authorisation
- 22Labelling
- 23Records
- 24Adverse events
- 25Inspection of sites
Annotations
Textual amendments
- F1
Sch. 2 Pt. 2 (paras. 14-25 entitled "Authorisation of autogenous vaccines, blood-banks, stem cell centres and products manufactured under the cascade") substituted for Sch. 2 Pt. 2 (paras. 14-19 entitled "Authorisation of manufacturers of autogenous vaccines"), Pt. 3 (paras. 20-24 entitled "Authorisation of blood banks"), Pt. 4 (paras. 25-29 entitled "Authorisation of manufacturers of products for administration under the cascade") and Pt. 5 (paras. 30-35 entitled "Authorisation of equine stem cell centres") (E.W.S.) (17.5.2024) by The Veterinary Medicines (Amendment etc.) Regulations 2024 (S.I. 2024/567), regs. 1(1), 92